Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sunshine Biopharma (SBFM) Current Assets (2016 - 2025)

Sunshine Biopharma's Current Assets history spans 14 years, with the latest figure at $26.9 million for Q4 2025.

  • For Q4 2025, Current Assets rose 3.42% year-over-year to $26.9 million; the TTM value through Dec 2025 reached $26.9 million, up 3.42%, while the annual FY2025 figure was $26.9 million, 3.42% up from the prior year.
  • Current Assets reached $26.9 million in Q4 2025 per SBFM's latest filing, down from $28.0 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $42.0 million in Q2 2022 to a low of $1.8 million in Q2 2021.
  • Average Current Assets over 5 years is $22.3 million, with a median of $25.9 million recorded in 2024.
  • Peak YoY movement for Current Assets: surged 5313.51% in 2021, then crashed 37.84% in 2023.
  • A 5-year view of Current Assets shows it stood at $2.2 million in 2021, then surged by 1143.83% to $27.3 million in 2022, then dropped by 8.87% to $24.9 million in 2023, then grew by 4.32% to $26.0 million in 2024, then increased by 3.42% to $26.9 million in 2025.
  • Per Business Quant, the three most recent readings for SBFM's Current Assets are $26.9 million (Q4 2025), $28.0 million (Q3 2025), and $27.9 million (Q2 2025).